Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells
Completed
- Conditions
- Hematologic Diseases
- Registration Number
- NCT02090803
- Lead Sponsor
- Institut de Cancérologie de la Loire
- Brief Summary
The purpose of this study is to assess the human herpes virus reactivation 6 post autologous stem cells in 196 patients. The aim of our study was to describe the incidence of reactivation of HHV-6 in patients requiring autologous HSCT and determine the pathogenic role in this target population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 189
Inclusion Criteria
- all patients hospitalized in the Hematology Clinic of Saint-Etienne and Clermont-Ferrand and receiving autologous hematopoietic stem cells, according to the decision of the Consultative Meeting Multidisciplinary service;
- Autologous recipients are included irrespective of causal hemopathy (myeloma, lymphoma, acute leukemia, mainly).
Exclusion Criteria
- The non-consenting patients or unable to give consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HHV-6 biological reactivation 40 days HHV-6 biological reactivation (blood viral load) is defined by a detectable viral load HHV-6 and\> 450 copies / mL on two occasions one week apart.
- Secondary Outcome Measures
Name Time Method Reconstitution of hematopoiesis 40 days Disease HHV-6 40 days Aplasia output or engraftment 40 days
Trial Locations
- Locations (3)
CHU Clermont-Ferrand
🇫🇷Clermont-Ferrand, France
HCL
🇫🇷Lyon, France
CHU Saint-Etienne - laboratoire de virologie
🇫🇷Saint-Etienne, France